Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Centers for Disease Control, Department of Health and Human Services.
Maintenance dialysis can be continued in patients with end stage renal disease who have manifestations of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) [now known as the human immunodeficiency virus], including the acquired immunodeficiency syndrome, or who are positive for antibody to HTLV-III/LAV. These patients can be dialyzed in hospital-based or free-standing dialysis units using conventional infection-control precautions. Transmission of HTLV-III/LAV is adequately prevented by standard blood and body fluid precautions, and disinfection and sterilization procedures.